Full-year results for the fiscal year ending June 2026 and earnings guidance for the fiscal year ending June 2027 were disclosed. Revenue is expected to continue growth, with profit improvement driven by contributions from the active pharmaceutical ingredient segment and improved cost structure. Progress at the Zao Second Factory and developments in new product launches are also noted.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"9273","jir_company_name":"KOA SHoji Holdings Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-08-07","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/9273-20260807-02.pdf","jir_short_summary":"Full-year results for the fiscal year ending June 2026 and earnings guidance for the fiscal year ending June 2027 were disclosed. Revenue is expected to continue growth, with profit improvement driven by contributions from the active pharmaceutical ingredient segment and improved cost structure. Progress at the Zao Second Factory and developments in new product launches are also noted.","jir_summary":"### Section heading\nThis document reports the results for the fiscal year ended June 2026 and the forecast for June 2027, focusing on revenue and profit trends, segment-specific dynamics, CAPEX\/investment plans, and financial soundness. It highlights the contribution of the active pharmaceutical ingredient segment, the operating status of the Zao Second Factory, and cost management initiatives as key points.\n\n### Section 2 heading\nDetails the basis and assumptions for the 2027 forecast, growth drivers in the API segment, competitive environment in the pharmaceutical segment, and business strategy in the mid-to-long term (allocation among API, pharmaceutical products, and adjustments). Includes progress on medium-to-long-term financial targets and risk factors.","jir_financial_highlights":"Revenue: 24,678 (YoY +8.2% (FY2025 \u2192 FY2026))\nOperating income: 5,270 (YoY \u25b23.8% (Forecast for FY2027 vs FY2026))\nNet income attributable to owners of parent: 35.9 (YoY +4.2%)","jir_category":"","jir_hashtags":"#KOASHoji Holdings Private #ConsiderShare Buyback #ExecutiveAppointments #MidTermPlan #PharmaSegment","jir_key_figures":"Revenue 24,678 million yen (FY2026)\nOperating income 5,270 million yen (FY2026)\nNet income attributable to owners of parent 3?5.9? hundred million yen (estimates; unclear figures left as-is)","jir_meta_title":"[KOA SHOJI HOLDINGS CO., LTD.] Financial Summary\uff5cForecast for FY2027","jir_meta_description":"Explanation of KOA SHOJI HOLDINGS's results for the fiscal year ended June 2026 and outlook for FY2027. Key points include revenue, operating income, net income trends, segment dynamics, API segment contributions, Zao Second Factory status, and progress toward the mid-to-long-term plan.","jir_og_title":"KOA SHOJI HOLDINGS Financial Summary: Results for 2026 and Outlook for 2027","jir_og_description":"Report of results for the fiscal year ended June 2026 and forecast for June 2027. Highlights include contributions from the API segment, progress at the Zao Second Factory, and mid-to-long-term plan developments.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"labels\\\":[\\\"2020\\\",\\\"2021\\\",\\\"2022\\\",\\\"2023\\\",\\\"2024\\\",\\\"2025\\\",\\\"2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[16340,17054,20253,22369,23693,24678,26600]}]}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating income Trend\", \"jir_chart_json_data\": \"{\\\"labels\\\":[\\\"2020\\\",\\\"2021\\\",\\\"2022\\\",\\\"2023\\\",\\\"2024\\\",\\\"2025\\\",\\\"2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating income\\\",\\\"data\\\":[5717,7019,7505,8389,8668,5270,5270]}]}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment revenue\", \"jir_chart_json_data\": \"{\\\"labels\\\":[\\\"API Segment\\\",\\\"Pharma Segment\\\"],\\\"datasets\\\":[{\\\"data\\\":[0,0]}]}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Profit margin analysis\", \"jir_chart_json_data\": \"{\\\"labels\\\":[\\\"2020\\\",\\\"2021\\\",\\\"2022\\\",\\\"2023\\\",\\\"2024\\\",\\\"2025\\\",\\\"2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating margin\\\",\\\"data\\\":[0,0,0,0,0,0,0]}]}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Forecast vs Actual\", \"jir_chart_json_data\": \"{\\\"labels\\\":[\\\"2022\\\",\\\"2023\\\",\\\"2024\\\",\\\"2025\\\",\\\"2026\\\",\\\"2027\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Forecast\\\",\\\"data\\\":[0]},{\\\"label\\\":\\\"Actual\\\",\\\"data\\\":[0]}]}\"}]","ir_related_company":57021,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-98793","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n